Co-Infection of COVID-19 and Pneumocystosis Following Rituximab Infusion—A Case Report
Immunocompromised patients with respiratory viral infections are at increased risk of fungal superinfections, including Pneumocystosis. Within the scope of the COVID-19 pandemic, <i>Pneumocystis jirovecii</i> co-infections are being increasingly reported. Differential diagnosis often cre...
Main Authors: | Michelle Dakowitz, Justyna Korus, Oktawia Mazanowska, Magdalena Krajewska, Dorota Kamińska |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Transplantology |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-3943/3/1/8 |
Similar Items
-
Gaining an Understanding of Pneumocystosis in Wales
by: Jonathan Ayling-Smith, et al.
Published: (2023-06-01) -
Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
by: Young Hoon Kim, et al.
Published: (2020-03-01) -
Are CMV and SARS-CoV-2 Infections Mutual Risk Factors in Kidney Transplant Recipients?
by: Julia Swist, et al.
Published: (2022-03-01) -
Prevalence of Pneumocystosis in Sub-Saharan Africa and Helminth Immune Modulation
by: Luis Fonte, et al.
Published: (2021-12-01) -
CMV Infection and Lymphopenia: Warning Markers of Pneumocystis Pneumonia in Kidney Transplant Recipients
by: Isabelle Eberl, et al.
Published: (2024-01-01)